PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
Yoon-Koo Kang,Jeong Hwan Yook,Young-Kyu Park,Jong Seok Lee,Young-Woo Kim,Jin Young Kim,Min-Hee Ryu,Sun Young Rha,Ik Joo Chung,Inho Kim,Sang Cheul Oh,Young Soo Park,Taeil Son,Mi Ran Jung,Mi Hwa Heo,Hark Kyun Kim,Cho-Hyun Park,Chang Hak Yoo,Jin-Hyuk Choi,Dae Young Zang,You Jin Jang,Ji Young Sul,Jong Gwang Kim,Beom Su Kim,Seung Hoon Beom,Sang-Hee Cho,Seung Wan Ryu,Myeong-Cherl Kook,Baek-Yeol Ryoo,Hyunki Kim,Moon-Won Yoo,Nam Su Lee,Sang Ho Lee,Gyunji Kim,Yeonju Lee,Jee Hyun Lee,Sung Hoon Noh +36 more
TLDR
Adjuvant chemotherapy after D2 gastrectomy is standard for resectable locally advanced gastric cancer (LAGC) in Asia as discussed by the authors, based on positive findings for perioperative chemotherapy in European ph...Abstract:
PURPOSEAdjuvant chemotherapy after D2 gastrectomy is standard for resectable locally advanced gastric cancer (LAGC) in Asia. Based on positive findings for perioperative chemotherapy in European ph...read more
Citations
More filters
Journal ArticleDOI
Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)
TL;DR: The 6th edition of the Japanese Gastric Cancer Treatment Guidelines was completed in July 2021, incorporating new evidence that emerged after publication of the previous edition as discussed by the authors , which consists of a text-based "Treatments" part and a "Clinical Questions" part including recommendations and explanations for clinical questions.
Journal ArticleDOI
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics
Zhen Luo,Mingfu Tian,George Q. Yang,Qiaoru Tan,Yubing Chen,Geng Li,Qiwei Zhang,Yongkui Li,Pin Wan,Jianguo Wu +9 more
TL;DR: The mechanisms of hypoxia signaling activation, the control of Hif signaling, and the function of HIF signaling in human health and diseases are reviewed to provide novel strategies for the design and development of therapeutic drugs.
Journal ArticleDOI
Signaling pathways and therapeutic interventions in gastric cancer
Zi-Ning Lei,Qiu-Xu Teng,Qin Tian,Wei Chen,Yuhao Xie,Kaiming Wu,Qianlin Zeng,Leli Zeng,Yihang Pan,Zhe S Chen,Yulong He +10 more
TL;DR: In this paper , the regulatory roles of signaling pathways in GC potential biomarkers, and therapeutic targets with an emphasis on recent discoveries are discussed, and the development of treatment for GC, particularly the challenges in developing precision medications, are discussed.
Journal ArticleDOI
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
Tae Han Kim,In Ho Kim,Seung Joo Kang,Mi-Rai Choi,Baek Hui Kim,Bang Wool Eom,Bum Jun Kim,Byung-Hoon Min,C. I. Choi,Cheol Min Shin,Chung Hyun Tae,Chung Sik Gong,Dong Jin Kim,Arthur K. Cho,Eun Jeong Gong,Geum Jong Song,Hyeon-Su Im,Hye Seong Ahn,Hyun Lim,Hyung-Don Kim,Jae-Joon Kim,Jeong Il Yu,Jeong Won Lee,Ji Yeon Park,Jwa Hoon Kim,Kyoung Doo Song,Minkyu Jung,Mi Ran Jung,Sang-Yong Son,Shin Hoo Park,S. Kim,Sung Hak Lee,Tae-Yong Kiim Kim,Woo Kyun Bae,Woong Sub Koom,Ye Seob Jee,Yoo Min Kim,Yoonjin Kwak,Young Suk Park,Hye Sook Han,Su Youn Nam,S. H. Kyeong +41 more
TL;DR: In this paper , the authors present a multidisciplinary-evidence based guideline for the treatment of gastric cancer in Korea, which is the revised version of previous evidence-based approach in 2018.
Journal ArticleDOI
The dawn of precision medicine in diffuse-type gastric cancer
Akira Ooki,Kensei Yamaguchi +1 more
TL;DR: The clinicopathological features and molecular profiles of DGC are summarized and a potential therapeutic target is highlighted based on the findings of pivotal clinical trials.
References
More filters
Journal ArticleDOI
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
David Cunningham,William H. Allum,Sally P. Stenning,Jeremy Thompson,Marianne Nicolson,J. Howard Scarffe,F. Lofts,Stephen Falk,Timothy Iveson,David Smith,Ruth E Langley,Monica Verma,Simon Weeden,Yu Jo Chua +13 more
TL;DR: In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival.
Journal ArticleDOI
Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction
John S. Macdonald,Stephen R. Smalley,Jacqueline Benedetti,Scott A. Hundahl,Norman C. Estes,Grant N. Stemmermann,Daniel G. Haller,Jaffer A. Ajani,Leonard L. Gunderson,J. Milburn Jessup,James A. Martenson +10 more
TL;DR: This investigation investigated the effect of surgery plus postoperative (adjuvant) chemoradiotherapy on the survival of patients with resectable adenocarcinoma of the stomach or gastroesophageal junction.
Journal ArticleDOI
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Shinichi Sakuramoto,M. Sasako,Toshiharu Yamaguchi,Taira Kinoshita,Masashi Fujii,Atsushi Nashimoto,Hiroshi Furukawa,Toshifusa Nakajima,Yasuo Ohashi,Hiroshi Imamura,Masayuki Higashino,Yoshitaka Yamamura,Akira Kurita,Kuniyoshi Arai +13 more
TL;DR: S-1 is an effective adjuvant treatment for East Asian patients who have undergone a D2 dissection for locally advanced gastric cancer and has a higher rate of overall survival than the surgery-only group.
Journal ArticleDOI
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
Marc Ychou,Valérie Boige,Jean-Pierre Pignon,Thierry Conroy,Olivier Bouché,Gilles Lebreton,Muriel Ducourtieux,Laurent Bedenne,Jean-Michel Fabre,B. Saint-Aubert,Jean Genève,Philippe Lasser,Philippe Rougier +12 more
TL;DR: In patients with resectable adenocarcinoma of the lower esophagus, GEJ, or stomach, perioperative chemotherapy using fluorouracil plus cisplatin significantly increased the curative resection rate, disease-free survival, and OS.
Journal ArticleDOI
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
Yung-Jue Bang,Young-Woo Kim,Han-Kwang Yang,Hyun Cheol Chung,Young-Kyu Park,Kyung Hee Lee,Keun Wook Lee,Yong Ho Kim,Sang Ik Noh,Jae Yong Cho,Young Jae Mok,Yeul Hong Kim,Jiafu Ji,Ta Sen Yeh,Peter Button,Florin Sirzen,Sung Hoon Noh +16 more
TL;DR: Adjuvant capecitabine plus oxaliplatin treatment after curative D2 gastrectomy should be considered as a treatment option for patients with operable gastric cancer.